格隆汇8月12日丨康龙化成(03759.HK)公告，康龙化成(北京)新药技术股份有限公司(以下简称“公司”)于2024年6月6日召开的2023年年度股东大会、2024年第一次A股类别股东大会及2024年第一次H股类别股东大会审议通过了《关于增加注册资本、修订<公司章程>的议案(一)》《关于增加注册资本、修订<公司章程>的议案(二)》。
近日，公司办理完成相关内容的工商变更登记手续，并取得了北京经济技术开发区市场监督管理局换发的《营业执照》。
Pharmaron (03759.HK) announced that Kanglong Huacheng (Beijing) Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") passed the resolution of "Proposal (1) for increasing registered capital and revising the " and "Proposal (2) for increasing registered capital and revising the " at the 2023 Annual General Meeting of Shareholders held on June 6, 2024, the 2024 1st Class A Shareholders' Meeting and the 2024 1st Class H Shareholders' Meeting.
Recently, the company has completed the commercial registration procedures for relevant content and obtained the Business License issued by the Market Supervision Administration of Beijing Economic and Technological Development Zone.
